File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice

TitleN-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice
Authors
Issue Date2015
Citation
Mediators of Inflammation, 2015, v. 2015, p. 283123 How to Cite?
AbstractTo expand the armamentarium of treatment for chronic kidney disease (CKD), we explored the utility of boosting endogenously synthesized N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), which is augmented by inhibition of the angiotensin converting enzyme. Male BALB/c mice underwent unilateral ureteral ligation (UUO) or sham operation and received exogenously administered Ac-SDKP delivered via a subcutaneous osmotic minipump or Captopril treatment by oral gavage. Seven days after UUO, there were significant reductions in the expression of both collagen 1 and collagen 3 in kidneys treated with Ac-SDKP or Captopril, and there was a trend towards reductions in collagen IV, alpha-SMA, and MCP-1 versus control. However, no significant attenuation of interstitial injury or macrophage infiltration was observed. These findings are in contrary to observations in other models and underscore the fact that a longer treatment time frame may be required to yield anti-inflammatory effects in BALB/c mice treated with Ac-SDKP compared to untreated mice. Finding an effective treatment regimen for CKD requires fine-tuning of pharmacologic protocols.
Persistent Identifierhttp://hdl.handle.net/10722/227369

 

DC FieldValueLanguage
dc.contributor.authorChan, GCW-
dc.contributor.authorYiu, WH-
dc.contributor.authorWu, H-
dc.contributor.authorWong, WLD-
dc.contributor.authorLin, M-
dc.contributor.authorHuang, XR-
dc.contributor.authorLan, HY-
dc.contributor.authorTang, SCW-
dc.date.accessioned2016-07-18T09:10:04Z-
dc.date.available2016-07-18T09:10:04Z-
dc.date.issued2015-
dc.identifier.citationMediators of Inflammation, 2015, v. 2015, p. 283123-
dc.identifier.urihttp://hdl.handle.net/10722/227369-
dc.description.abstractTo expand the armamentarium of treatment for chronic kidney disease (CKD), we explored the utility of boosting endogenously synthesized N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), which is augmented by inhibition of the angiotensin converting enzyme. Male BALB/c mice underwent unilateral ureteral ligation (UUO) or sham operation and received exogenously administered Ac-SDKP delivered via a subcutaneous osmotic minipump or Captopril treatment by oral gavage. Seven days after UUO, there were significant reductions in the expression of both collagen 1 and collagen 3 in kidneys treated with Ac-SDKP or Captopril, and there was a trend towards reductions in collagen IV, alpha-SMA, and MCP-1 versus control. However, no significant attenuation of interstitial injury or macrophage infiltration was observed. These findings are in contrary to observations in other models and underscore the fact that a longer treatment time frame may be required to yield anti-inflammatory effects in BALB/c mice treated with Ac-SDKP compared to untreated mice. Finding an effective treatment regimen for CKD requires fine-tuning of pharmacologic protocols.-
dc.languageeng-
dc.relation.ispartofMediators of Inflammation-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleN-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice-
dc.typeArticle-
dc.identifier.emailYiu, WH: whyiu@hku.hk-
dc.identifier.emailTang, SCW: scwtang@hku.hk-
dc.identifier.authorityTang, SCW=rp00480-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1155/2015/283123-
dc.identifier.hkuros259633-
dc.identifier.volume2015-
dc.identifier.spage283123-
dc.identifier.epage283123-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats